Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06328764 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CS-101 in Patients With β-thalassemia

StatusEnrolling by Invitation
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 9, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv5
  2. Primary completion date: Dec 31, 2025 to Jul 31, 2026
    • Study completion date: Jan 30, 2026 to Jul 31, 2026
    v4
  3. Trial status: Recruiting to Enrolling by Invitation
    • Site details revised
    v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 20, 2024 to Mar 19, 2024
    • Site details revised
    • Study title shortened, about 10 words
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 in treating β-thalassemia.
Trial Details
NCT Number NCT06328764
Lead Sponsor CorrectSequence Therapeutics Co., Ltd
Collaborators: First Affiliated Hospital of Guangxi Medical University
Conditions
(from sponsor)		 Beta-Thalassemia
Related terms beta-Thalassemia
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov